Pharmaceutical Drug Analog Screening and Forecasting Online Portal
SA-BRC announces the release of a premium online pharmaceutical drug analog screening and forecasting portal “Pukka” for United States Market. Pukka provides a database of 100 brands (and growing) spread across various disease categories such as Oncology, Diabetes, Cardiovascular, Immunology, Vaccines, Pain Management, Anti-Infectives, etc.
Houston, TX, September 15, 2016 --(PR.com)-- The web based portal allows a subscriber to select over 30 critical parameters in order to screen appropriate analogs that can be further reviewed in detail alongside U.S. sales data right from their launch year up to 2015 as historical data and 2016-2022 as forecast period.
In terms of pharmaceutical jargon, analogs or analogues are drugs of varying similarity. These similarities may be in terms of numerous parameters such as order of entry in market, pharmacologic class, epidemiology, molecular similarities, days of therapy, formulation type and/or disease specificity. Forecasting the demand of a new drug is tricky because it has no history/historical commercial data that can be used to predict the future. Analogs play an important role in helping the forecast teams build a forecast model to estimate the sales of the new drug.
For further details, please click the link: sa-brc.com/pukka-analog-forecast-tool.php
This tool provides access to qualitative and quantitative (U.S. sales) data of over 100 brands for United States market with more brands being added every year. Comparison models frequently present inaccurate predictions if the brands being considered have multiple indications or if brands being considered are only top selling prescriptions, however Pukka considers only those drugs that are FDA approved for single indication only and comprises of both top selling brands as well as those performing below par thus presenting an extremely realistic view of the comparison result.
Pukka currently offers analog forecasting for major disease categories such as oncology, metabolic disorder, cardiovascular, central nervous system, skin disease, respiratory, pain management, hematology, urology, autoimmune and autoinflammatory diseases. The database also presents market revenue for United States from approval to 2015 and a forecast of sales to 2022 for all 100 brands! It provides qualitative information on over 36 parameters such as adherence, persistence, molecule, order of entry, efficacy rate, disease condition, clinical manifestation, treatment type, formulation type, orphan designation, pharmacologic class, indication, disease category, route of administration, indication specificity, days of therapy, dosing frequency, cost per day, reimbursement tier, current ownership and others. The market forecast has been estimated using the most accurate prediction systems using base values gathered from annual reports and patient based forecasting techniques.
For free demo access, please mail us at: sales@sa-brc.com; john@sa-brc.com
SA-BRC Team
In terms of pharmaceutical jargon, analogs or analogues are drugs of varying similarity. These similarities may be in terms of numerous parameters such as order of entry in market, pharmacologic class, epidemiology, molecular similarities, days of therapy, formulation type and/or disease specificity. Forecasting the demand of a new drug is tricky because it has no history/historical commercial data that can be used to predict the future. Analogs play an important role in helping the forecast teams build a forecast model to estimate the sales of the new drug.
For further details, please click the link: sa-brc.com/pukka-analog-forecast-tool.php
This tool provides access to qualitative and quantitative (U.S. sales) data of over 100 brands for United States market with more brands being added every year. Comparison models frequently present inaccurate predictions if the brands being considered have multiple indications or if brands being considered are only top selling prescriptions, however Pukka considers only those drugs that are FDA approved for single indication only and comprises of both top selling brands as well as those performing below par thus presenting an extremely realistic view of the comparison result.
Pukka currently offers analog forecasting for major disease categories such as oncology, metabolic disorder, cardiovascular, central nervous system, skin disease, respiratory, pain management, hematology, urology, autoimmune and autoinflammatory diseases. The database also presents market revenue for United States from approval to 2015 and a forecast of sales to 2022 for all 100 brands! It provides qualitative information on over 36 parameters such as adherence, persistence, molecule, order of entry, efficacy rate, disease condition, clinical manifestation, treatment type, formulation type, orphan designation, pharmacologic class, indication, disease category, route of administration, indication specificity, days of therapy, dosing frequency, cost per day, reimbursement tier, current ownership and others. The market forecast has been estimated using the most accurate prediction systems using base values gathered from annual reports and patient based forecasting techniques.
For free demo access, please mail us at: sales@sa-brc.com; john@sa-brc.com
SA-BRC Team
Contact
SA-BRC
John Whitmore
+1(832)-426-3701
www.sa-brc.com
http://sa-brc.com/pukka-analog-forecast-tool.php
John Whitmore
+1(832)-426-3701
www.sa-brc.com
http://sa-brc.com/pukka-analog-forecast-tool.php
Contact
Multimedia
Pharmaceutical Drug Analog Screening and Forecasting Online Portal
The web based portal allows a subscriber to select over 30 critical parameters in order to screen appropriate analogs that can be further reviewed in detail alongside U.S. sales data right from their launch year up to 2015 as historical data and 2016-2022 as forecast period.
Categories